Clinical Trial Update: Long-term Follow-up of Patients With Spinal Muscular Atrophy Treated With OAV101 in Clinical Trials [Phase 3]

View source ↗

Summary

This clinical trial update reports the long-term follow-up of patients with spinal muscular atrophy treated with OAV101 in Phase 3 trials.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Spinal Muscular Atrophy

Drugs mentioned

• OAV101

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Spinal Muscular Atrophy (SMA) | Phase 3 | Status: RECRUITING